2002•Unpublished venueRequires access

Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection

Melissa D. Neuwelt

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine which NNRTI, EFV or NVP, is associated with greater virological suppression when given in combination with two NRTIs as part of initial antiretroviral combination therapy in HIV‐infected ART‐naïve adults. EFV‐containing and NVP‐containing triple‐drug regimens will be compared with regards to therapeutic efficacy, using plasma HIV RNA concentration as a surrogate marker for clinical progression.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Nevirapine, Efavirenz, Medicine, Nucleoside Reverse Transcriptase Inhibitor, Reverse-transcriptase inhibitor, Antiretroviral therapy, Virology, Human immunodeficiency virus (HIV)